Kaiserman Nadia, Vinker Shlomo, Kaiserman Igor
Hebrew University Medical School, Jerusalem, Israel.
Curr Eye Res. 2009 Apr;34(4):304-10. doi: 10.1080/02713680902741670.
To investigate the effect of statins on the risk for age-related macular degeneration (AMD) treated with photodynamic therapy (PDT).
All members in one district of a health maintenance organization in Israel, older than 50 years (n = 139,894), were included. PDT procedures for AMD (775 procedures; 283 patients) and filled statin prescriptions between 1999 and 2002 (471,232 prescriptions; 29,417 patients) were documented.
For all age groups, PDT was more prevalent in statin users. Among statin users, the age adjusted proportion of patients undergoing PDT for wet AMD was 0.27% (95% confidence interval (CI): 0.20-0.34%), compared to 0.16% (95% CI: 0.14-0.18%) among non-users (p = 0.002, chi2 test, relative risk = 1.66 (95% CI: 1.29-2.19)). After correction for age, gender, socioeconomic status, place of birth, place of residence, hyperlipidemia, hypertension, ischemic heart disease, diabetes, and congestive heart failure, statins did not have any additional effect on the risk for undergoing PDT for wet AMD. In a case control analysis, statin use in PDT patients was similar to their use by matched controls (odds ratio = 1.0; 95% CI = 0.8-1.3).
This study does not support a beneficial effect of statin use for reducing the risk for wet AMD requiring PDT.
研究他汀类药物对接受光动力疗法（PDT）治疗的年龄相关性黄斑变性（AMD）风险的影响。
纳入以色列一家健康维护组织一个地区所有年龄大于50岁的成员（n = 139,894）。记录了1999年至2002年间AMD的PDT治疗程序（775例；283例患者）以及他汀类药物处方（471,232张处方；29,417例患者）。
在所有年龄组中，PDT在他汀类药物使用者中更为普遍。在他汀类药物使用者中，湿性AMD接受PDT治疗的年龄调整后比例为0.27%（95%置信区间（CI）：0.20 - 0.34%），而非使用者为0.16%（95% CI：
0.14 - 0.18%）（p = 0.002，卡方检验，相对风险 = 1.66（95% CI：1.29 - 2.19））。在对年龄、性别、社会经济地位、出生地、居住地、高脂血症、高血压、缺血性心脏病、糖尿病和充血性心力衰竭进行校正后，他汀类药物对湿性AMD接受PDT治疗的风险没有任何额外影响。在病例对照分析中，PDT患者使用他汀类药物的情况与其匹配对照相似（优势比 = 1.0；95% CI = 0.8 - 1.3）。
本研究不支持使用他汀类药物降低需要PDT治疗的湿性AMD风险的有益作用。
